setting priorities, investing wisely and providing care for all. ISBN 978-92-4-000129-9 (electronic version) “Cancer will develop in one in every five people before the age of 75.”
~ 29.5 million (+67%) 2018: > 9.5 million cancer-related deaths worldwide. 2024: ~ 16.4 million (+ 74%) *National Cancer Institute report, 25 Sept 2020 Inconsistent treatment caused by the ever changing lifestyle and restriction of pandemic NON CURABLE CANCER Chronic lymphocytic leukaemia Chronic myeloid leukaemia Myeloma Pleural mesothelioma Secondary brain tumours / breast / bone / liver / lung cancer CURRENT MEDICAL TREATMENT Chemotherapy [Severe Side Effect] Radiotherapy [Damage Tissues] Surgery [Unable to remove all cell] Immunotherapy [Less than 50% success rate] Combination of all [Drugs interaction risk] Gene Therapy [Potentially severe health risk] Thermal Ablations [Damage to blood vessel/Nerve] Tumor Treating Fields (TTF) [Less effective to broad cancer] SIDE EFFECTS Physically weak Emotionally affected Restricted Movement *The list is too long to fit here* What's the problem with current therapy?
Free from Injection / Incision / Radiation Ability to penetrate through air layers Does not affected the healthy cells Remote data transmission on patient health status Artificial Intelligence real time data analytics Bespoke feedback, analysis, monitoring and follow up Highly effective and safe with low voltage Electro-Capacitive Cancer Therapy (ECCT) Electric Field Cancer Therapy
spread across the body cell Keep healthy cell Pending Certifications & Insurance support Largest market for broad areas like Breast and Lung Cancer Increasing purchase power and demand for less life side effect cure Pandemic slowed down treatment and weaken body of survival. Preventive function Pandemic restrict funding and delayed progress S W O T S W T Effective on solid tumor. Registered medical device Insurance Claimable REVOTERA TTF Not effective on broad areas cancer High voltage kills healthy cells REVOTERA! Treat the untreatable Proven methodology Painless treatment Cost effective Monthly: $3,000 Monthly: $20,000++
4.2 Million WORLD SPENT SPENDING POWER In 2016, the world spent US$ 7.5 trillion on health, representing almost 10% of global GDP WHO estimates the coverage of cancer treatment by 2030 would increased to US$ 140 billion between 2020 and 2030. 4.2 million out of 18.1 million incidence recorded in 2018 comes from Lung and Breast Cancer. REVOTERA proven effective against both. *WHO 2020 Report 1 SINGLE COMPETITON A rare and meaningful opportunity with only single competition who had proven the market viability yet market share still largely available. COVID-19 SURIVAL Possibility increased of lung and organ cancer for post Covid survival due to weakened overall health, especially for those with unhealthy living lifestyle. 200 Million
5th Year 7th Year 10thYear COMPETITOR REVOTERA 1st Pilot Trial 2004 2nd Phase Recurrent Trial 2006 1st FDA Approval 2011 IPO raised $158m 2015 Revenue grew 26% per annum 2018 Net income of $20 million in 2020 2020 Electrical Device Approved Patent Submitted 1st Pilot Trial 2021 Patent Approval CE Approval EMEA Approval Pilot & Pivotal Clinical Studies 2022 APAC Approval 2nd Phase Clinical Studies 2024 Completed 5th year survival studies for FDA submissions 2025 FDA Approval IPO 2026/27 Target Net Income of min $20 million 2030 4th Year 6th Year 11th Year 15th Year 18th Year TIMELINE & POSITION Company Founded 2000 Company Founded Tested Cured 15,000 patients 2020 8x Speed 20th Year 1.6x Speed 2.2x Speed 2x Speed
1st FDA approval for Pre- market Medical Device follow by IPO fund raising. 2024: Expand market with 2.0 with enhanced features and higher coverage 2022: Patent approved CE Approval Launch as Electrical Device
masakiokuda
satomasahiro2005
bengo4com
occhi
jtakeda
takuroabe
jozono
hiracky16
recruitengineers
oasis1994liveforever
takonda
kenichiodo
codingconduct
keithpitt
tmiket
rasagy
addyosmani
csswizardry
inesmontani
aleyda
schroneko
andyhume
rocio
